Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214214 | 0.88 | HTR2C (0.42) | PNMTHTR2CHTR2AHTR2B | |
| SCHEMBL18820432 | 0.86 | HTR2C (0.42) | PNMTHTR2CHTR2AHTR2BADRA2A | |
| Hydrochloric Acid SCHEMBL4195138 | 0.86 | HTR2C (0.41) | PNMTHTR2CHTR2AHTR2B | |
| SCHEMBL20038338 | 0.84 | PNMT (0.31) | PNMT | |
| SCHEMBL26457284 | 0.83 | CYP3A4 (0.36) | PNMTCYP3A4HTR2CHTR2AHTR2B | |
| SCHEMBL1019803 | 0.83 | CYP3A4 (0.41) | PNMTCYP3A4HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL3881128 | 0.81 | CYP3A4 (0.40) | PNMTCYP3A4HTR2CHTR2AHTR2B | |
| SCHEMBL3410304 | 0.77 | CYP3A4 (0.44) | PNMTCYP3A4HTR2CHTR2BADRA2A | |
| SCHEMBL13090252 | 0.76 | CYP3A4 (0.38) | PNMTCYP3A4HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL17965646 | 0.75 | CYP3A4 (0.43) | PNMTCYP3A4HTR2CHTR2BADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2021121294-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2021-06-24 | — | — | WO | disclosed |
| US-20210040118-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2021-02-11 | — | — | US | disclosed |
| US-10253025-B2 | Method of making tetrahydronaphthyridinyl nonanoic acid compounds | SCIFLUOR LIFE SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | PNMT 4226/4885CYP3A4 3328/4885HTR2C 2362/4885 |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | PNMT 2330/4885CYP3A4 6/4885HTR2C 625/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | PNMT 4722/4885CYP3A4 4655/4885HTR2C 2559/4885 |
| US-10253025-B2 | Method of making tetrahydronaphthyridinyl nonanoic acid compounds | NISCH, SLC10A1, AANAT | PNMT 175/4885CYP3A4 346/4885HTR2C 496/4885 |
| US-20210040118-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | PNMT 2664/4885CYP3A4 2133/4885HTR2C 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.